{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:07:47Z","timestamp":1789193267301,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":213,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jhep.2021.01.046","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T18:01:12Z","timestamp":1613066472000},"page":"1225-1233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Maria","family":"Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.01.046_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J\u00a0Natl Canc Inst"},{"key":"10.1016\/j.jhep.2021.01.046_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.01.046_bib3","first-page":"S0140","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Bruix","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.01.046_bib4","article-title":"Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial","volume":"36","author":"Abou-Alfa","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.01.046_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2021.01.046_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.046_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/hep.24670","article-title":"Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques","volume":"54","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","author":"Galle","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.01.046_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","author":"Lens","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","article-title":"Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin-free treatment","volume":"38","author":"Kozbial","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.01.046_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib16","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.046_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jvh.13280","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy\u2014results from the German Hepatitis C-Registry","volume":"27","author":"Knop","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.01.046_bib18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.01.046_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.046_bib21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","author":"Verna","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.01.046_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity\u2014LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.01.046_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.046_bib27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2016.04.033","article-title":"Direct antiviral agents and risk for HCC early recurrence: much ado about nothing","volume":"65","author":"Camm\u00e0","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.05.036","article-title":"Reply to \u201cDirect antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: much ado about nothing","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0037-1601349","article-title":"Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?","volume":"37","author":"Reig","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.01.046_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib35","article-title":"Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan","author":"Chi","year":"2019","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.jhep.2021.01.046_bib36","article-title":"Impact of direct-acting antiviral therapy for hepatitis C\u2013related hepatocellular carcinoma","volume":"15","author":"Lin","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.01.046_bib37","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hep.30988","article-title":"Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west","volume":"71","author":"Dang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/v11050406","article-title":"Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents","volume":"11","author":"Sanduzzi-Zamparelli","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2021.01.046_bib40","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","author":"Sapena","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.01.046_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13357","article-title":"A\u00a0meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma","author":"Cabibbo","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.01.046_bib42","first-page":"5188","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"13","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.046_bib43","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.046_bib44","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north American cohort study","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.046_bib45","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","article-title":"The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib46","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000000770","article-title":"Compensated cirrhosis and 20 mm Hg: a point of No return?","author":"Reverter","year":"2020","journal-title":"Am Coll Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.046_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082132","article-title":"Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: a decision analysis","volume":"12","author":"Cabibbo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2021.01.046_bib48","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.046_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27729","article-title":"Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib","author":"Iavarone","year":"2015","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T14:51:20Z","timestamp":1726066280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0168827821000982"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.046","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}